Clear, direct answers
Frequently Asked Questions
These are the questions judges, clinicians, and engineers reliably ask. We answer them plainly and conservatively, based on design intent and the way antimicrobial blue-light research is typically discussed.
Core questions
No. BlueLight Bandage is designed around visible blue light near 405 nm and explicitly avoids ultraviolet exposure.
Visible blue light is non-ionizing; UV disinfection relies on different mechanisms and carries different considerations.
Many bacteria contain endogenous chromophores (often described as porphyrin-like molecules). Blue light can excite these molecules,
generating reactive oxygen species (ROS). ROS can damage microbial membranes, proteins, and nucleic acids, leading to inactivation.
Outcomes depend on exposure conditions and dose.
BlueAid is designed as a complement to standard care, not a replacement. The project focuses on non-pharmacologic,
localized antimicrobial support. Clinical decisions about antibiotics are made by clinicians and depend on diagnosis, risk, and guidelines.
Thermal management is treated as a first-order constraint. The bandage concept includes a thermal barrier layer and design choices intended to
reduce heat transfer to the wound interface. Exposure time caps and conservative settings further reduce risk.
The project is in an early-stage prototyping and laboratory validation phase. We focus on controlled experiments with matched controls and
conservative reporting. See Research & Evidence for how we frame results.
BlueLight Bandage is a research and development concept and does not provide medical guidance. The design goal is outpatient usability
with visible light, controlled exposure, and safety constraints. Any real-world use would require appropriate validation and oversight.
If your question isn’t listed, contact us through Join Us — we prefer direct, specific questions.